Quest Diagnostics Financial Model
Healthcare Services Company Financials Example (Free Excel Download)
Quest Diagnostics is a leading provider of diagnostic information services, offering clinical testing that ranges from routine blood work to complex genetic and oncology diagnostics.
professionals from Deloitte
Used by professionals from
About this model
This model provides a comprehensive equity valuation and scenario analysis platform for an equity research analyst to forecast Quest Diagnostics' core testing volumes, evaluate the accretive impact of recent acquisitions like LifeLabs, and determine a fair value per share.
Quest Diagnostics is a leading provider of diagnostic information services, offering clinical testing that ranges from routine blood work to complex genetic and oncology diagnostics. The company operates a massive hub-and-spoke laboratory network across the United States and Canada, processing millions of test requisitions annually to support hospitals, physicians, and consumers.
- Diagnostic Information Services (DIS): Accounts for over 95% of consolidated net revenues. This segment provides clinical testing services to patients, clinicians, and hospitals.
- Diagnostic Solutions (DS): Accounts for less than 5% of revenues. This includes risk assessment services for life insurance companies and healthcare IT solutions.
- Key Geographies: Primarily the United States, with a significantly expanded Canadian footprint following the 2024 acquisition of LifeLabs.
- Business Model: Asset-heavy laboratory network with high fixed costs, creating significant operating leverage where incremental testing volumes drive margin expansion.
- Competitive Position: Operates as a duopoly in the US independent lab market alongside Labcorp, holding significant scale advantages over regional and hospital-based labs.
- Recent Major Events: In 2024, Quest acquired LifeLabs for approximately $985 million (CAD 1.35 billion), adding roughly $710 million in annual revenue. The company also formed a major lab services joint venture with Corewell Health in Michigan and acquired PathAI's diagnostic laboratory.
The downloadable Quest Diagnostics financial model includes SEC-sourced historical financials, forecast assumptions, core operating schedules, and valuation outputs in an Excel workbook built for review and scenario analysis.
A turnkey financial model
Live formulas, no hardcoded values
Outputs are driven by live formulas, so the workbook updates from its assumptions instead of relying on hardcoded results.
All assumptions in one tab
Inputs are clearly marked in the Assumptions tab and separated from calculations, making it clear what to change and what to leave intact.
Statements always balancing
For integrated-statement models, the balance sheet, cash flow, and supporting schedules tie through properly.
Distinct schedules for clarity
Debt, working capital, taxes, and cash flow can get messy quickly. We group calculations in clear schedules, not across disconnected tabs.
No hidden macros or external links
There are no unexplained external workbook links or macros to undermine auditability or portability.
Changes flow through the model
Update a key driver and see the impact carry through the forecast, financing, and return outputs. We never use hardcoded numbers in formulas.
Historicals & AssumptionsQuest Diagnostics financial modelCompany, Historicals & Assumptions used
Source: SEC EDGAR · values in USD
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $10.79B | $9.88B | $9.25B | $9.87B | $11.04B |
| Gross profit | $4.21B | $3.43B | $3.05B | $3.24B | $3.67B |
| Operating income | $2.38B | $1.43B | $1.26B | $1.35B | $1.56B |
| Net income | $2.00B | $946.0M | $854.0M | $871.0M | $992.0M |
Forecast assumptions
Defaults used in the downloadable model. Forecast horizon: FY2026–FY2030.
See 8 moreSee less
How to build a detailed financial model for Quest Diagnostics
A complete walkthrough of every driver, margin, working-capital input, and capital-allocation assumption used in the downloadable model.
Revenue Deep Dive
Diagnostic Information Services (DIS)
- Segment Name: Diagnostic Information Services
- Revenue Driver Formula: Total Requisition Volume x Average Revenue per Requisition
- Historical Growth Rate: 6% to 14% recently, heavily influenced by M&A activity and the normalisation of post-pandemic base testing.
- Key Growth Levers and Headwinds: Growth is driven by hospital outreach acquisitions, an ageing population, and advanced diagnostics (e.g., Alzheimer's blood tests, oncology). Headwinds include Medicare reimbursement pressures under the Protecting Access to Medicare Act (PAMA) and managed care pricing negotiations.
- Pricing Dynamics: Highly regulated and contractual. Pricing depends on payer mix (Medicare, Medicaid, commercial insurers, patient self-pay) and test mix (routine vs. advanced diagnostics).
- Revenue Recognition Notes: Recognised over time as testing services are completed and results are reported to the ordering physician.
- Seasonality: First quarter is typically the weakest due to winter weather disrupting patient visits and the resetting of patient deductibles.
Diagnostic Solutions (DS)
- Segment Name: Diagnostic Solutions
- Revenue Driver Formula: Service Contracts + Software Subscriptions
- Historical Growth Rate: Flat to low single digits.
- Key Growth Levers and Headwinds: Dependent on life insurance application volumes and the adoption of healthcare IT platforms.
- Pricing Dynamics: Contractual B2B pricing.
Cost Structure
Variable Costs / COGS
- Line Items: Reported as "Cost of services". Includes laboratory supplies, reagents, direct laboratory labour, specimen collection and logistics (courier network), and facility costs for patient service centres.
- Gross Margin Range: 32.5% to 34.5% over the last 5 years.
- Key Input Costs: Reagents, fuel for logistics networks, and clinical labour wages.
- Operating Leverage: High. The logistics network and central lab facilities represent fixed or step-function costs; incremental test volume drops through to gross margin at a high rate.
Operating Expenses
- SG&A: Reported as "Selling, general and administrative". Includes sales force compensation, billing and revenue cycle management, and corporate overhead. Typically runs at 16% to 18% of revenue.
- Amortisation of Intangible Assets: Significant due to the roll-up acquisition strategy (e.g., LifeLabs, hospital outreach labs).
- Restructuring / One-Time Charges: Frequent charges related to Project Nova (order-to-cash modernisation) and integration costs for acquired laboratories.
Margin Profile
- Gross Margin: 33.0% to 34.0%.
- Operating Margin (Reported): 13.0% to 14.0%.
- Operating Margin (Adjusted): 15.0% to 16.0% (excluding amortisation and restructuring).
- Margin Trend: Expanding slightly as the company digests acquisitions, implements automation, and scales its joint ventures (e.g., Corewell Health).
Balance Sheet Structure
- Total Assets: Approximately $13 billion to $14 billion.
- Key Asset Categories: Property, plant and equipment (laboratories), accounts receivable, and a massive goodwill balance.
- Goodwill & Intangibles: Represents over 50% of total assets, reflecting decades of industry consolidation and recent large deals like LifeLabs.
- Working Capital Profile:
- Days Sales Outstanding (DSO): 40 to 50 days. Revenue cycle management is complex due to third-party payer denials and patient co-pays.
- Days Inventory Outstanding (DIO): 15 to 25 days (reagents and lab supplies turn over quickly).
- Days Payable Outstanding (DPO): 35 to 45 days.
- Net Working Capital: Generally positive but tightly managed.
- PP&E: Consists of regional mega-labs, rapid response labs, and thousands of patient service centres. Useful lives for lab equipment are typically 5 to 7 years.
- Right-of-Use Assets: Material, as the company leases the vast majority of its patient service centres and fleet vehicles.
Capital Expenditure & Investment
- Capex as % of Revenue: 3.5% to 4.5%.
- Maintenance vs. Growth: Roughly 60% maintenance (replacing lab equipment, IT upgrades) and 40% growth (Project Nova, new facility build-outs).
- Major Capex Programmes: Project Nova (modernising the billing and order-to-cash systems) and automation robotics for central laboratories.
- M&A Pattern: Serial acquirer. The company executes both transformational deals (LifeLabs) and bolt-on hospital outreach lab acquisitions.
- Typical Acquisition Multiple: 8x to 12x EV/EBITDA post-synergies.
Debt & Capital Structure
- Total Debt: Approximately $4.5 billion to $5.5 billion, elevated recently due to the LifeLabs acquisition.
- Debt/EBITDA Ratio: Targets 2.5x to 3.0x.
- Credit Rating: Investment grade (typically Baa2/BBB).
- Key Debt Instruments: Senior unsecured notes with staggered maturities, supported by a revolving credit facility.
- Interest Rate Profile: Primarily fixed-rate bonds, with a weighted average cost of debt around 4.0% to 4.5%.
- Share Repurchase Programme: Highly active. The company routinely uses excess free cash flow to buy back shares, often repurchasing 1% to 3% of the market cap annually.
- Dividend Policy: Consistent dividend grower. The annual payout is currently $3.20 per share, representing a payout ratio of roughly 30% to 35% of adjusted EPS.
Cash Flow Characteristics
- Operating Cash Flow Conversion: Very strong, typically 1.2x to 1.5x of reported net income due to heavy non-cash amortisation and depreciation.
- Free Cash Flow Margin: 8% to 11% of revenue.
- Major Non-Cash Items: Depreciation, amortisation of acquired intangibles, and stock-based compensation.
- Working Capital Impact: Modest use of cash during periods of high growth, but generally stable.
- Capex Intensity: Low to moderate, allowing for significant free cash flow generation.
Sheet Structure
- Assumptions: Hardcoded drivers for volume growth, pricing, margins, tax rates, and capital allocation.
- Revenue Build: Detailed schedule forecasting DIS Requisition Volume, Revenue per Requisition, and DS segment revenue.
- M&A Schedule: Tracks acquired revenue, integration costs, and amortisation schedules for recent deals like LifeLabs and Corewell Health.
- Income Statement: Consolidated view from Net Revenues down to Net Income and EPS (both GAAP and Adjusted).
- Balance Sheet: Assets, Liabilities, and Equity, driven by working capital schedules and debt tranches.
- Cash Flow Statement: Operating, Investing, and Financing cash flows, linking net income to the ending cash balance.
- Working Capital Schedule: Calculates Accounts Receivable, Inventory, and Accounts Payable based on DSO, DIO, and DPO.
- Depreciation & Amortisation: Waterfall schedules for existing PP&E, new capex, and acquired intangible assets.
- Debt Schedule: Tracks senior notes, revolving credit facility, interest expense, and mandatory repayments.
- DCF Valuation: Unlevered free cash flow build, WACC calculation, terminal value, and implied share price.
Key Financial Relationships
- DIS Revenue = Total Requisitions x Average Revenue per Requisition
- Total Requisitions = Prior Year Requisitions x (1 + Organic Volume Growth + M&A Volume Growth)
- Average Revenue per Requisition = Prior Year Revenue per Requisition x (1 + Pricing/Mix Yield)
- Total Net Revenues = DIS Revenue + DS Revenue
- Cost of Services = Total Net Revenues x (1 - Gross Margin %)
- SG&A Expense = Total Net Revenues x SG&A Margin %
- Adjusted Operating Income = Total Net Revenues - Cost of Services - SG&A Expense (excluding amortisation and restructuring)
- Accounts Receivable = (Total Net Revenues / 365) x DSO
- Inventory = (Cost of Services / 365) x DIO
- Accounts Payable = (Cost of Services / 365) x DPO
- Free Cash Flow = Cash Provided by Operations - Capital Expenditures
- Adjusted Net Income = Reported Net Income + Amortisation (net of tax) + Restructuring (net of tax)
- Adjusted EPS = Adjusted Net Income / Diluted Shares Outstanding
Cross-Sheet Dependencies
- The Revenue Build feeds the top line of the Income Statement and drives the Accounts Receivable calculation on the Working Capital Schedule.
- The M&A Schedule feeds incremental volume into the Revenue Build, adds Goodwill and Intangibles to the Balance Sheet, and pushes Amortisation into the Depreciation & Amortisation sheet.
- The Working Capital Schedule calculates the change in net working capital, which feeds the Cash Flow Statement.
- The Debt Schedule calculates interest expense, which feeds the Income Statement, creating a circular reference if interest expense impacts cash balances that subsequently pay down revolving debt.
- The Cash Flow Statement determines the ending cash balance and debt paydown, which link back to the Balance Sheet to ensure it balances.
Sign Convention
- Revenues, assets, and cash inflows are represented as positive numbers.
- Expenses, liabilities, capital expenditures, and cash outflows are represented as negative numbers.
- Margins and ratios are represented as positive percentages.
- The Balance Sheet check must be formulated as Assets + (Liabilities + Equity) = 0, assuming Liabilities and Equity are negative, or Assets - Liabilities - Equity = 0 if all are positive. The builder must strictly follow the convention that expenses are negative in summation formulas.
Things Most Likely to Go Wrong
- M&A Revenue Double Counting: The builder might apply organic growth rates to a base that already includes unannualised M&A revenue, overstating future volumes.
- GAAP vs Adjusted EPS Confusion: Quest heavily promotes Adjusted EPS (which excludes amortisation). The model must clearly bridge GAAP Net Income to Adjusted Net Income.
- Requisition Volume vs Pricing Mix: Payer mix shifts (e.g., more Medicare) can lower the Revenue per Requisition even if Volume grows. The model must treat these as independent variables.
- PAMA Reimbursement Cuts: Medicare fee schedule cuts can create step-function drops in pricing. The model must allow for manual pricing overrides in specific forecast years.
- Amortisation Run-Off: Intangible amortisation from historical acquisitions will decline over time unless replenished by new M&A. Straight-lining amortisation as a percentage of revenue will artificially depress long-term GAAP margins.
- Working Capital Seasonality: DSO typically spikes in Q1 due to deductible resets. Annual models might miss this, but quarterly models must account for it.
- Share Count Reductions: Failing to model the aggressive share repurchase programme will result in understated EPS forecasts.
- Joint Venture Accounting: The Corewell Health Co-Lab relationship adds significant revenue at lower margins. Applying historical consolidated margins to this new revenue stream will overstate operating income.
Validation Checks
- "Gross margin should be in the 32.5% to 34.5% range; flag if outside this band."
- "Adjusted Operating Margin should remain between 15.0% and 16.5%."
- "Capex as a percentage of revenue should run between 3.5% and 4.5%."
- "DSO must remain between 40 and 50 days; a rising DSO indicates revenue cycle management issues."
- "Debt/EBITDA should remain below 3.0x to maintain the investment-grade credit rating."
- "Balance sheet must balance: Total Assets = Total Liabilities + Equity in every period."
- "Free Cash Flow conversion (FCF / Adjusted Net Income) should be greater than 0.9x."
- "Dividend payout ratio should remain between 30% and 40% of Adjusted EPS."
Key Assumptions (Default Values)
| Assumption | Default Value | Unit | Rationale |
|---|---|---|---|
| DIS Organic Volume Growth | 3.0 | % | Normalised base business growth driven by demographics and hospital outreach. |
| DIS M&A Volume Growth | 4.0 | % | Reflects recent acquisitions like LifeLabs and Corewell Health joint venture. |
| DIS Revenue per Requisition Growth | 0.5 | % | Modest growth as advanced diagnostics mix offsets Medicare pricing pressures. |
| DS Segment Revenue Growth | 2.0 | % | Stable, low-growth profile of the life insurance risk assessment business. |
| Gross Margin | 33.5 | % | Aligns with recent historical averages and management guidance. |
| SG&A as % of Revenue | 17.5 | % | Reflects ongoing Project Nova investments and wage inflation. |
| Effective Tax Rate | 24.0 | % | Standard corporate tax rate blended with state and international (Canadian) exposures. |
| Capex as % of Revenue | 4.0 | % | Historical average required to maintain the lab network and fund IT upgrades. |
| Days Sales Outstanding (DSO) | 45 | Days | Standard revenue cycle collection period for clinical laboratories. |
| Days Inventory Outstanding (DIO) | 20 | Days | Fast turnover of testing reagents and lab supplies. |
| Days Payable Outstanding (DPO) | 40 | Days | Standard vendor payment terms. |
| Annual Share Repurchases | 350 | $ Millions | Consistent return of capital to shareholders via open market purchases. |
| Annual Dividend per Share | 3.20 | $ | Based on the recently increased quarterly dividend of $0.80 per share. |
| Cost of Debt | 4.5 | % | Weighted average interest rate on existing senior notes and revolving credit. |
| WACC | 7.5 | % | Discount rate for DCF, reflecting the stable, defensive nature of the business. |
| Terminal Growth Rate | 2.0 | % | Long-term growth rate aligned with inflation and population growth. |
Data Sources & Benchmarks
- Filings: SEC EDGAR for 10-K and 10-Q filings; Quest Diagnostics Investor Relations portal for earnings presentations and Project Nova updates.
- Key Peers: Labcorp (LH) is the primary direct competitor. Sonic Healthcare (SHL.AX) and NeoGenomics (NEO) serve as secondary benchmarks for specific testing segments.
- Industry Data: American Clinical Laboratory Association (ACLA) for regulatory updates; Centers for Medicare & Medicaid Services (CMS) for Clinical Laboratory Fee Schedule (CLFS) pricing data.
- Consensus Estimates: FactSet or Bloomberg for forward-looking analyst estimates on Requisition Volume and Revenue per Requisition.
Sources
- Quest Diagnostics Q4 2024 and Q4 2025 Earnings Press Releases (Investor Relations Website)
- Quest Diagnostics 2024 Form 10-K (SEC EDGAR)
- PR Newswire: Quest Diagnostics Completes Acquisition of LifeLabs (August 2024)
- PR Newswire: Quest Diagnostics Reports Second Quarter 2025 Financial Results; Raises Guidance (July 2025)
- PR Newswire: Quest Diagnostics Reports Third Quarter 2025 Financial Results (October 2025)
Do more with the Quest Diagnostics model
Frequently asked
What services does Quest Diagnostics provide?+
Quest Diagnostics is a leading provider of diagnostic information services, offering clinical testing that ranges from routine blood work to complex genetic and oncology diagnostics. The company operates a massive hub-and-spoke laboratory network across the United States and Canada, processing millions of test requisitions annually.
How does Quest Diagnostics generate its revenue?+
Quest Diagnostics primarily generates revenue through its Diagnostic Information Services (DIS) segment, which accounts for over 95% of consolidated net revenues by providing clinical testing services. A smaller portion comes from Diagnostic Solutions (DS), including risk assessment services for life insurance companies and healthcare IT solutions.
What are Quest Diagnostics' typical capital expenditure needs?+
Quest Diagnostics' capital expenditure typically ranges from 3.5% to 4.5% of revenue. Roughly 60% of this capex is for maintenance, such as replacing lab equipment and IT upgrades, while 40% is allocated to growth initiatives like Project Nova and new facility build-outs.
What are the key assets on Quest Diagnostics' balance sheet?+
Quest Diagnostics' balance sheet features total assets of approximately $13 billion to $14 billion, with key categories including property, plant and equipment (laboratories), accounts receivable, and a substantial goodwill balance. Goodwill and intangibles represent over 50% of total assets, reflecting decades of industry consolidation and recent large deals.
What is the purpose of the downloadable Quest Diagnostics financial model?+
The downloadable Excel model provides a comprehensive equity valuation and scenario analysis platform for equity research analysts. It allows users to forecast Quest Diagnostics' core testing volumes, evaluate the accretive impact of recent acquisitions like LifeLabs, and determine a fair value per share.
How does Quest Diagnostics' business model benefit from scale?+
Quest Diagnostics operates an asset-heavy laboratory network with high fixed costs, which creates significant operating leverage. This means that incremental testing volumes drive margin expansion, leveraging their extensive hub-and-spoke network across the US and Canada. The company holds significant scale advantages as a duopoly in the US independent lab market.
Have more financial modelling questions? Contact us
Created by ex-finance professionals
Hey, I’m Alex and I created Finamodel.
Over my years in the finance industry I kept building the same models over and over again. Same structure, same assumptions, different logo. So I started building frameworks to turn them into clean, reusable templates.
Every model here is one I’d actually use for a client, and I personally vet each one before it goes up.
I’m not an expert in every industry, but I’ve built enough models to know what belongs in one. And when something is completely foreign to me, I reach out to my network for experts to work on our models with us.
Having a template library on hand cuts a first build from hours to minutes.
Need help finding your model? You’ll find me in the Finamodel app!
Other Healthcare Services Company Financial Models
Browse another company in the same sector.
Cardinal Health
Cardinal Health is a global healthcare services and products company that provides customised solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centres, and clinical laboratories.
Cencora
Cencora, formerly AmerisourceBergen, is one of the largest global pharmaceutical sourcing and distribution services companies.
Charles River Laboratories
Charles River Laboratories is a leading early-stage contract research organisation (CRO) that provides essential products and services to help pharmaceutical and biotechnology companies, government agencies, and academic institutions accelerate their research and drug development efforts.
DaVita
DaVita is a leading provider of kidney care services, primarily operating outpatient dialysis centres for patients with end-stage renal disease, while also managing value-based care arrangements and an expanding international dialysis network.
HCA Healthcare
HCA Healthcare is the largest for-profit operator of health care facilities in the United States, managing 190 hospitals and approximately 2,400 ambulatory sites of care.
Henry Schein
Henry Schein is the world's largest provider of health care solutions to office-based dental and medical practitioners, operating a global supply chain distributing over 300,000 products alongside software and e-services.
IQVIA
IQVIA is a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, formed through the merger of Quintiles and IMS Health.
Labcorp
Laboratory Corporation of America Holdings (Labcorp) is a global life sciences company that provides comprehensive clinical laboratory and end-to-end drug development services.
Explore more Healthcare financial model templates.
